Apr 12 2024 This Week in Cardiology

Apr 12, 2024

Cardiologist John Mandrola, MD, covers ACC Recap including Impella CP in STEMI, REDUCE-AMI challenging beta-blockers post-MI, Prevent trial showing reduced cardiac events with preventive PCI, and EMPACT-MI on SGT2 inhibitors in post-MI care. Topics include device enthusiasm caution, industry payments influencing LVAD utilization, challenging cardiology practices with beta blockers, and plaque vulnerability identification and treatment implications.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 2min

Impella vs. Standard Care in Cardiogenic Shock Trial: A Critical Analysis

02:26 • 6min

Analysis of Industry Payments and LVAD Utilization Among Cardiologists

07:59 • 3min

Challenging Cardiology Practices: Beta Blockers and Plaque Vulnerability

10:46 • 14min

Analysis of SGT2 Inhibitors in Post Myocardial Infarction Care and Mortality Benefits

25:09 • 4min

ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. DanGer-Shock Trial

Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz

Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659

Published DanGer Shock Study https://www.nejm.org/doi/full/10.1056/NEJMoa2312572
JAMA Research letter https://jamanetwork.com/journals/jama/article-abstract/2817457

II. REDUCE-AMI Trial

New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8

Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663

REDUCE-AMI paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
Meta-analysis: Beta Blockers for MI https://doi.org/10.1016/j.amjmed.2014.05.032

III. PREVENT Trial

Preventive PCI for Vulnerable Plaques Reduces Cardiac Events

https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc

Preventive Coronary Stents: Not There Yet

https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr

PREVENT https://doi.org/10.1016/S0140-6736(24)00413-6

IV. EMPACT MI trial of Empagliflozin in the Post-MI setting

Empagliflozin Fails to Reduce Events After Acute MI

https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn

EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care https://www.medscape.com/viewarticle/1000684
EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051
DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508
Kaul thread https://x.com/kaulcsmc/status/1776611935842165029
Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net